Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Herbal tablets tested for stress relief and brain boost

NCT ID NCT05757050

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether ReFocus tablets, containing herbs Scutellaria baicalensis and Crataegus, can improve stress, memory, attention, sleep, and wellbeing. Thirty-six healthy adults who felt stressed took the supplement or a placebo for 14 days in a crossover design. Researchers measured changes in cognitive performance and mood using computer tests and questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ReFocus tablets (Scutellaria baicalensis and Crataegus)
What this could lead to
If it works, this could point toward a natural supplement to help manage everyday stress and improve mental focus.
What could go wrong
This is a small, early-stage trial in healthy volunteers, not patients. Results may not apply to people with clinical stress or anxiety, and the supplement may show no benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

Mar 2023

Finished

Sep 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18-75 Exclusion Criteria: * • If participant scores less 12, or less, on the Perceived Stress Scale * Have any pre-existing medical condition/illness which will impact taking part in the study \* NOTE: the explicit exceptions to this are controlled hyper/hypothyroidism, hay fever, high cholesterol and reflux-related conditions * Are currently taking prescription medications \*NOTE: the explicit exceptions to this are contraceptive treatments for female participants, thyroid medications, topical skin treatments and those medications used in the treatment of high cholesterol and reflux-related conditions; and those taken 'as needed' in the treatment of asthma and hay fever * Have high blood pressure (systolic over 159 mm Hg or diastolic over 99 mm Hg). NOTE: that we must measure this in the lab using our blood pressure monitors and can only use our measurements to assess eligibility rather than home or GP readings * Have a Body Mass Index (BMI) outside of the range 18.5-35 kg/m2 * Are pregnant, seeking to become pregnant or lactating * Have learning and/or behavioural difficulties such as dyslexia or ADHD * Have a visual impairment that cannot be corrected with glasses or contact lenses (including colour-blindness) * Smoke tobacco or vape nicotine or use nicotine replacement products (if you have recently quit smoking or using replacements you must have stopped using them altogether for a period of 3 months before participating in this study) * Have excessive caffeine intake (\>500 mg per day). Note: This will be calculated at screening but feel free to query this with the researcher prior to attendance * Have relevant food allergies/ intolerances/ sensitivities (Please discuss with researcher prior to attendance if you are unsure of relevance) * Have taken antibiotics within the past 4 weeks * Have taken dietary supplements e.g. vitamins, omega 3 fish oils etc. in the last 4 weeks (Note: participation is possible following a 4-week supplement washout prior to participating and for the duration of the study on the proviso that the supplements are taken are out of choice and are not medically prescribed or advised). Existing and consistent use of vitamin D supplements and protein shakes are permitted * Have any health condition that would prevent fulfilment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken) * Are unable to complete all of the study assessments * Are currently participating in other clinical or nutrition intervention studies, or have in the past 4 weeks * Have been diagnosed with/ undergoing treatment for alcohol or drug abuse in the last 12 months * Have been diagnosed with/ undergoing treatment for a psychiatric disorder in the last 12 months, including a medical diagnosis of anxiety or depression. * Suffers from frequent migraines that require medication (more than or equal to 1 per month) * Have oral disease * Have any known active infections * Does not have a bank account (required for payment) * Are non-compliant with regards treatment consumption

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mental health wellness 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Northumbria University

    Newcastle upon Tyne, Tyne & Wear, NE1 8ST, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.